Skip to main content
. 2019 Apr 5;134(1):22–29. doi: 10.1182/blood.2019000215

Table 1.

Baseline patient characteristics

Variable N (%*) or median (range)
Total 30 (100)
Age, y 33 (20-69)
Sex
 Male 16 (53)
 Female 14 (47)
Frontline therapy
 A(B)VD 24 (80)
 BV-A(B)VD 1 (3)
 ABVE-PC 1 (3)
 BEACOPP 2 (7)
 RCHOP/REPOCH 2 (7)
Prior brentuximab exposure 6 (20)
Prior nivolumab or pembrolizumab exposure 6 (20)
Prior radiotherapy 7 (23)
Conditioning regimen
 BEAM 30 (100)
Risk factors
 Primary refractory disease 17 (57)
 Relapse within 12 mo 5 (17)
 Extranodal disease at relapse 8 (27)
  At least 1 of above 3 factors 26 (87)
 Residual disease after salvage 3 (10)
 B symptoms at relapse 2 (7)
 >1 salvage therapy 5 (17)
  At least 1 of above 6 factors 27 (90)
  At least 2 of above 6 factors 12 (40)
Disease status at study entry (post-ASCT)
 Partial remission 2 (7)
 Complete remission 28 (93)

A(B)VD, doxorubicin, bleomycin, vinblastine, and dacarbazine; ABVE-PC, doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone; BEAM, carmustine, etoposide, cytarabine, and melphalan; BV, brentuximab vedotin; RCHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; REPOCH, rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin.

*

Percentages may not add to 100 because of rounding.

With rituximab in 1 patient.

Given after ABVD in 1 additional patient.